Pharmacokinetics and toxicity of idarubicin in the rat

被引:0
作者
Kuhlmann, O
Hofmann, S
Weiss, M [1 ]
机构
[1] Univ Halle Wittenberg, Dept Pharmacol, Sect Pharmacokinet, D-06097 Halle Saale, Germany
[2] Univ Halle Wittenberg, Dept Cardiothorac Surg, D-06097 Halle Saale, Germany
关键词
idarubicin; idarubicinol; rat; lung; pharmacokinetics;
D O I
10.1007/BF03226374
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
This study was designed to examine the pharmacokinetics and toxicity of idarubicin (IDA) in rats. In two groups of rats IDA was infused either into the V. iugularis interna or into the A. carotis communis, respectively. The venous plasma concentration of IDA and its primary metabolite idarubicinol (IDOL) were measured up to 48 hours by high - performance liquid chromatography (HPLC) with fluorescence detection. The weights of the rats and the levels of haemoglobin, leukocytes, and thrombocytes were recorded. The plasma concentration - time data were analysed, assuming a biexponential disposition curve, both by the traditional (two - stage) method and by population pharmacokinetic modelling. The basic pharmacokinetic parameters clearance (CL = 27.0 ml min(-1)), mean disposition residence time (MDRT = 519.2 min), and volume of distribution at steady state (V-ss = 12.51) were estimated for IDA. The mean residence time (MRT) of the generated IDOL was 2982.5 min. No significant differences between pre- and postpulmonal injection were found in the pharmacokinetics and pharmacodynamics of IDA. The mean survival time of 13.3 days is attributed to a severe myelosuppression.
引用
收藏
页码:215 / 219
页数:5
相关论文
共 50 条
  • [1] Pharmacokinetics and toxicity of idarubicin in the rat
    Olaf Kuhlmann
    Stefan Hofmann
    Michael Weiss
    European Journal of Drug Metabolism and Pharmacokinetics, 2001, 26 : 215 - 219
  • [2] Pharmacokinetics of idarubicin in the isolated perfused rat lung:: effect of cinchonine and rutin
    Kuhlmann, O
    Hofmann, HS
    Müller, SP
    Weiss, M
    ANTI-CANCER DRUGS, 2003, 14 (06) : 411 - 416
  • [3] Oral idarubicin pharmacokinetics -: correlation of trough level with idarubicin area under curve
    Schleyer, E
    Kühn, H
    Unterhalt, M
    Kaufmann, CC
    Kern, W
    Braess, J
    Sträubel, G
    Hiddemann, W
    LEUKEMIA, 1997, 11 : S15 - S21
  • [4] Oral idarubicin pharmacokinetics - Correlation of trough level with idarubicin area under curve
    Schleyer, E
    Kuhn, S
    Ruhrs, H
    Unterhalt, M
    Kaufmann, CC
    Kern, W
    Braess, J
    Straubel, G
    Hiddemann, W
    LEUKEMIA, 1996, 10 (04) : 707 - 712
  • [5] DEVELOPMENTAL TOXICITY AND PHARMACOKINETICS OF ORAL AND INTRAVENOUS PHENYTOIN IN THE RAT
    ROWLAND, JR
    BINKERD, PE
    HENDRICKX, AG
    REPRODUCTIVE TOXICOLOGY, 1990, 4 (03) : 191 - 202
  • [6] COMPARISON OF THE INTRACELLULAR PHARMACOKINETICS OF DAUNORUBICIN AND IDARUBICIN IN PATIENTS WITH ACUTE-LEUKEMIA
    TIDEFELT, U
    SUNDMANENGBERG, B
    PAUL, C
    LEUKEMIA RESEARCH, 1994, 18 (04) : 293 - 297
  • [7] Pharmacokinetics and tissue distribution of idarubicin and its active metabolite idarubicinol in the rabbit
    Looby, M
    Linke, R
    Weiss, M
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 1997, 39 (06) : 554 - 556
  • [8] Toxicity and pharmacokinetics of isolated lung perfusion with cisplatin in rat
    Kaneda Y.
    Liu D.
    Brooks A.
    Abolhoda A.
    Labow D.
    Burt M.E.
    Ginsberg R.J.
    The Japanese Journal of Thoracic and Cardiovascular Surgery, 2001, 49 (7): : 443 - 448
  • [9] Effects of idarubicin and idarubicinol on rat coronary resistance and vasoconstrictor responsiveness of isolated aorta and mesentery
    Weiss, M
    Giessler, C
    Kang, WK
    ANTI-CANCER DRUGS, 2006, 17 (01) : 69 - 74
  • [10] Pharmacokinetics and cerebrospinal fluid penetration of daunorubicin, idarubicin, and their metabolites in the nonhuman primate model
    Berg, SL
    Reid, J
    Godwin, K
    Murry, DJ
    Poplack, DG
    Balis, FM
    Ames, MM
    JOURNAL OF PEDIATRIC HEMATOLOGY ONCOLOGY, 1999, 21 (01) : 26 - 30